Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER®, RE-COVER™ II, and RE-MEDY™

It is unclear whether thrombophilia causes resistance to anticoagulant therapy. Post hoc analyses of data from RE-COVER®, RE-COVER™ II, and RE-MEDY™ were performed to compare dabigatran etexilate with warfarin for the treatment and prevention of venous thromboembolism (VTE) in patients with thrombophilia or antiphospholipid antibody syndrome (APS). There were no significant differences in symptomatic VTE/VTE-related deaths between dabigatran etexilate and warfarin in patients with or without thrombophilia. All bleeding event categories were less frequent with dabigatran etexilate than with warfarin, regardless of whether patients had thrombophilia, no thrombophilia, or were not tested. However, these differences did not reach significance in every group. In patients with APS, there was no significant difference in VTE/VTE-related deaths between the two treatment arms. Rates of bleeding events tended to be lower with dabigatran etexilate than with warfarin, reaching statistical significance for any bleeding event. In conclusion, the efficacy and safety of dabigatran etexilate were not significantly affected by the presence of thrombophilia or APS. ClinicalTrials.gov RECOVER Identifier: NCT00291330; RECOVER II Identifier: NCT00680186; RE-MEDY Identifier: NCT00329238

[1]  T. Porter,et al.  Limited evidence for diagnosing and treating “non-criteria obstetric antiphospholipid syndrome” , 2015, Thrombosis and Haemostasis.

[2]  G. Rodgers,et al.  New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome , 2014, American journal of hematology.

[3]  K. Moder,et al.  Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients , 2014, Thrombosis and Haemostasis.

[4]  J. Weitz,et al.  Evolving use of new oral anticoagulants for treatment of venous thromboembolism. , 2014, Blood.

[5]  G. Piazza.  Thrombophilia testing, recurrent thrombosis, and women's health. , 2014, Circulation.

[6]  S. Goldhaber,et al.  Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis , 2014, Circulation.

[7]  G. Raskob,et al.  Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. , 2013, The New England journal of medicine.

[8]  S. Goldhaber,et al.  Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism , 2013 .

[9]  Giancarlo Agnelli,et al.  Oral apixaban for the treatment of acute venous thromboembolism. , 2013, The New England journal of medicine.

[10]  F. García-Bragado Dalmau.  [Oral Rivaroxaban for the treatment of symptomatic pulmonary embolism]. , 2013, Revista clinica espanola.

[11]  G. Raskob,et al.  Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. , 2012, The New England journal of medicine.

[12]  Bruce L Davidson,et al.  Oral rivaroxaban for symptomatic venous thromboembolism. , 2010, The New England journal of medicine.

[13]  S. Goldhaber,et al.  Dabigatran versus warfarin in the treatment of acute venous thromboembolism. , 2009, The New England journal of medicine.

[14]  M. Monreal,et al.  Thrombophilia testing in patients with venous thromboembolism. Findings from the RIETE registry. , 2009, Thrombosis Research.

[15]  M. Makris.  Thrombophilia: grading the risk. , 2009, Blood.

[16]  Chan Jun-mi,et al.  International Consensus Statement on an Update of the Classification Criteria for Definite Antiphospholipid Syndrome(APS) , 2008 .

[17]  Paolo Prandoni,et al.  The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies. , 2007, Haematologica.

[18]  G. Hankey,et al.  Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. , 2006, Archives of internal medicine.